N/A
N=770
Strategies to Assist With Management of Pain
Chronic Low Back Pain
Bottom Line
View on ClinicalTrials.gov: NCT03115359 ↗Enrolled (actual)
770
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Composite Pain Severity — 5.6; 5.6 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mindfulness Based Therapy (Behavioral); Cognitive Behavioral Therapy (Behavioral)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of Wisconsin, Madison
- Primary completion
- Jan 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Composite Pain Severity |
5.5; 5.5 | — |
| PRIMARY Composite Pain Severity |
5.5; 5.5 | — |
| PRIMARY Physical Function |
43.4; 43.2 | — |
| PRIMARY Physical Function |
43.4; 43.2 | — |
| PRIMARY Average Pain Severity |
5.4; 5.5 | — |
| PRIMARY Average Pain Severity |
5.4; 5.5 | — |
| SECONDARY Health-Related Quality of Life (Physical Health) |
30.5; 30.0 | — |
| SECONDARY Health-Related Quality of Life (Physical Health) |
30.5; 30.0 | — |
| SECONDARY Health-Related Quality of Life (Mental Health) |
43.5; 45.9 | — |
| SECONDARY Health-Related Quality of Life (Mental Health) |
43.5; 45.9 | — |
| SECONDARY Average Daily Opioid Dose |
144; 192 | — |
| SECONDARY Average Daily Opioid Dose |
144; 192 | — |
Summary
Chronic low back pain (CLBP) has no known effective treatment. While often treated with long-term opioid therapy, opioids do not work well for many patients and can cause serious side effects, including addiction, poorer mental health, and overdose death. Even when paired with a standard-of-care cognitive behavioral therapy (CBT), results are limited. Patients, families and clinicians are very interested in using alternative treatments for CLBP, especially complementary and integrative treatments such as mindfulness meditation (MM). MM helps train the mind to bring non-judgmental and accepting attention to present-moment experiences such as pain. MM offers an active and safe self-care approach to chronic pain that contrasts with the passive and potentially harmful nature of opioid treatment, and may prove more effective than CBT in helping improve health and well-being, and reduce reliance on opioids in adults with opioid-treated CLBP. Although this hypothesis is supported by early research, including a pilot study by the Principal Investigator, evidence on MM's effectiveness in this population is inconclusive, presenting a critical knowledge gap.
With input from patients, family members, and clinicians, the Investigators have designed a study to address this gap and propose a clinical trial that will compare the effectiveness of MM to standard-of-care CBT in opioid-treated CLBP. Based on the existing research, it is hypothesized that MM training will lead to a larger reduction in pain intensity, increase in physical function, improvement in quality of life, and decrease in daily opioid dose, as compared to CBT training, with benefits of MM especially notable in adults with worse mood, anxiety or unhealthy opioid-use behaviors who often experience more severe symptoms of CLBP and less improvement in response to existing therapies.
To test these hypotheses, 766 adults with opioid-treated CLBP will be randomly assigned into one of two 8-week treatment groups: MM (383 participants) that will receive the MM training or CBT (383 participants) that will receive the CBT training. Due to the COVID-19 pandemic-related restrictions, the study protocol was modified in October 2020 so that the study can be completed virtually.
The effectiveness of MM versus CBT will be assessed over a 12-month period with patient-reported measures, recommended by experts and endorsed by our stakeholder partners, including patients with opioid-treated CLBP, their families and clinicians.
Eligibility Criteria
Inclusion Criteria (per self-report): English-speaking; age ≥ 21 years old; chronic low back pain (defined as a pain in lumbosacral region or sciatica for ≥3 months), with an average daily back pain score ≥3 on a 0-10 numerical rating scale (question from the Brief Pain Inventory), treated with ≥30 mg/day of morphine-equivalent dose for ≥3 months; at least moderate CLBP-related disability (≥21 score on the Oswestry Disability Index); capable of giving informed consent; willing to complete the study activities.
Exclusion Criteria (per self-report): prior formal Mindfulness Meditation or Cognitive Behavioral Therapy training; current pregnancy; diagnosis of borderline personality, delusional, or bipolar (mania) disorder; inability to safely or reliably participate in the study.
Data sourced from ClinicalTrials.gov (NCT03115359). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.